TAM Summit

TAM Summit

November 20th, 2019 | Boston, MA

Deep Dive into the Systematic Approach of Allosteric Modulator Therapeutics

Registration Agenda
Summit Partner
Summit Partner

Scigilian Software is a leading life sciences solutions provider specializing in cloud and on-premise solutions that address the collaboration challenges in a distributed research environment. Scigilian provides solutions designed to orchestrate and streamline the workflows between a research organization and its CRO partners and other external research organizations. The workflows enabled by Scigilian solutions include but are not limited to those for managing sample inventory, performing material acquisition and logistics, preparing near-assay ready plates, scheduling assays, tracking experiments, and analyzing and viewing data.

Learn More

Key Features
Senior Networking

Connect with key decision-makers and industry influencers in this intimate setting to generate genuine relationships and takeaways

Exclusively Dedicated

The TAM Summit is the first to be solely dedicated to exploring the Allosteric Modulator industry

Impactful Day

We know you’re busy people.  That’s why TAM Summit is constructed as a one-day feast of inspiring learning with a jam-packed agenda

The inaugural TAM Summit is designed to highlight current drug discovery challenges, strategies and case histories towards the design of allosteric modulator therapeutics

Adrian Gill, Vice President of Chemistry & CMC, Revolution Medicines

2019 Speakers

Adrian Gill
Adrian Gill
Vice President of Chemistry & CMC
Revolution Medicines
Adrian Gill
Vice President of Chemistry & CMC
Revolution Medicines

Adrian aspires to not only be a great medicinal chemistry leader, but a leader of great medicinal chemists. Adrian has over 22 years of industry experience in roles of increasing responsibility across a diverse range of disease areas in both large pharma and biotech environments.

He has previously worked for Roche, Astex Therapeutics and AstraZeneca, where he was the head of Medicinal Chemistry for the CVMD iMed in Gothenberg, Sweden. Adrian is currently VP of Medicinal Chemistry at Revolution Medicines, a clinical stage biotech company based in Redwood City, California.

During his career to date, Adrian has been heavily involved in the identification of over 15 clinical candidates across a variety of disease areas including AT7519 and AT9283 at Astex Therapeutics, for the treatment of a range of human cancers, and AZD4017 at Astrazeneca, for the treatment of diabetes and obesity.

At Revolution Medicines, Adrian leads the Medicinal Chemistry team and is a co-inventor of the allosteric SHP2 phosphatase chemical series that delivered the development candidate, RMC-4630.  In addition, he is a co-inventor of a bi-steric chemical series with dual modes of action to selectively target mTORC1 that recently delivered the development candidate, RMC-5552.  In addition, Adrian has authored over 20 publications in peer-reviewed journals and is a named inventor on over 40 small molecule patent applications.

Adrian received his Ph.D. in synthetic organic chemistry from the University of Sussex, U.K., where he focused on synthetic methodology towards the total synthesis of rapamycin, and has a bachelor’s degree in applied chemistry from the University of Salford, U.K.

Michael Eck
Michael Eck
Professor of Biological Chemistry & Molecular Pharmacology, Harvard Medical School
Dana-Farber Cancer Institute
Michael Eck
Professor of Biological Chemistry & Molecular Pharmacology, Harvard Medical School
Dana-Farber Cancer Institute

Michael J. Eck MD, Ph.D. is Professor of Biological Chemistry and Molecular Pharmacology at the Dana-Farber Cancer Institute and Harvard Medical School. Dr. Eck’s research centers on the structural biology of cell signaling and cancer. His research group uses biochemical and biophysical approaches, including X-ray crystallography and cryo-electron microscopy, to study kinase regulation and to unravel the mechanisms by which oncogenic mutations alter kinase activity and drug sensitivity. The Eck lab is working to develop novel, mutant-selective therapeutics targeting oncogenic kinases, include EGFR mutations in lung cancer, JAK2 mutations in myeloproliferative disorders, and BRAF alterations in diverse human cancers. 

Dr. Eck earned his Bachelor of Science in Electrical Engineering from Rice University in 1985, and his MD and Ph.D. degrees from the University of Texas Southwestern Medical School in 1991. He trained as a Postdoctoral Fellow with Dr. Stephen Harrison at Children’s Hospital, Boston and Harvard Medical School before joining the faculty of the Dana-Farber Cancer Institute and Harvard Medical School in 1996. 

Geraldine Harriman
Geraldine Harriman
Co-Founder & Chief Scientific Officer
HotSpot Therapeutics
Geraldine Harriman
Co-Founder & Chief Scientific Officer
HotSpot Therapeutics

Working for more than 20 years in drug discovery & early development, Gerry’s strong experience allows her to move seamlessly from one area of science to another, guiding cross-disciplinary problem solving. Drawn to medicine at an early age, she was fascinated to learn how the body works at its most basic level. This, together with her love of innovation, chemistry and biology culminated into a desire to discover new medicines.

Prior to co-founding HotSpot, Gerry served as Vice President and Head of ACC Program at Nimbus Therapeutics, where she led the effort to discover a leading drug for NASH. She also served as Vice President at Galenea, co-led the Inflammation Therapeutic Area at Millennium Pharmaceuticals, and was a founding member of the scientific team at LeukoSite.

Gerry received her Ph.D. in Chemistry at the University of Rhode Island and completed her post-doc fellowship at The University of Kansas.

Bob Copeland
Bob Copeland
Chief Scientific Officer
Accent Therapeutics
Bob Copeland
Chief Scientific Officer
Accent Therapeutics

Robert A. Copeland, Ph.D., co-founded Accent Therapeutics in September 2017 and serves as its President and Chief Scientific Officer. He was formerly President of Research and Chief Scientific Officer of Epizyme, Inc. and before that, Vice President of Cancer Biology in the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline. He has contributed to drug discovery and development efforts leading to 18 investigational new drugs entering human clinical trials. These include the cancer drugs foretinib, afuresertib, pinometostat, tazemetostat, Tafinlar (dabrafenib) and Mekinist (trametinib) and the antibiotic Altabax (retapamulin). Robert has contributed more than 200 publications to the scientific literature, holds 14 issued U.S. patents and has authored five books in the areas of protein science and enzymology. He is a member of the editorial board of Molecular Cancer Therapeutics, the advisory board of the Dana-Farber Accelerator Fund and multiple biotechnology scientific advisory boards. He received his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Research Fellow at the California Institute of Technology. In 2016, Robert was elected a fellow of the American Association for the Advancement of Science.

Pascal Fortin
Pascal Fortin
Senior Vice President
Relay Therapeutics
Pascal Fortin
Senior Vice President
Relay Therapeutics

Pascal is Senior Vice President, Head of Biochemistry, Biophysics and Structural Biology, overseeing and evolving the experimental drug discovery platform at Relay.

Prior to Relay, Pascal served as the head of Molecular Pharmacology and Biological Chemistry in Oncology at the Novartis institutes for Biomedical Research. He led a group working at the interface of biochemistry, biophysics and cellular biology, investing significant efforts towards the development of allosteric molecules modulating the function of hard-to-drug cancer targets.

Before joining Novartis, Pascal completed a postdoctoral fellowship at Harvard Medical School, where he studied the biosynthetic logic behind natural product biosynthesis. His postdoctoral work led to the discovery of a transglutaminase homologue as a condensation catalyst in antibiotic assembly lines. It also led to a great appreciation of the many ways natural small molecules modulate protein function. Pascal obtained BS in biochemistry at Laval University and obtained a PhD at the University of British Columbia, studying the enzymology underlying aromatic compounds catabolism.

Maria-Jesus Blanco
Maria-Jesus Blanco
Senior Director of Medicinal Chemistry
Sage Therapeutics
Maria-Jesus Blanco
Senior Director of Medicinal Chemistry
Sage Therapeutics

Maria-Jesus Blanco has almost 20 years of experience working in drug discovery in the pharmaceutical industry (pharma and biotech). She is currently Senior Director of Medicinal Chemistry at Sage Therapeutics (Cambridge, MA), covering early drug discovery to IND and clinical studies. Previously, Maria was Director of Discovery Chemistry Research & Technologies at Eli Lilly (Indianapolis, IN). She has lead teams and contributed to the delivery of >11 clinical candidates mainly for CNS indications. Dr. Blanco obtained her B.S and Ph.D. degrees in Chemistry from the University of Santiago de Compostela, Spain, followed by postdoctoral positions at Massachusetts Institute of Technology with Prof. Masamune and Univ. Strasbourg, France with 2016 Nobel Laureate Prof. Sauvage. Maria has >75 publications, patents and presentations. She is an industrial councilor for the American Chemical Society medicinal chemistry division, mentor and science advocate.

Marc Semigran
Marc Semigran
Senior Vice President of Medical Sciences
MyoKardia
Marc Semigran
Senior Vice President of Medical Sciences
MyoKardia

Marc Semigran, M.D., joined MyoKardia in December, 2016. Previously, he led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director, from 2004 to 2016. In addition, he was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network. Dr. Semigran was a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School. He has published more than 140 peer-reviewed papers in cardiomyopathy, heart failure and cardiac transplantation, and served as editor for a leading textbook on heart failure. Dr. Semigran is a recipient of numerous National Institutes of Health and industry research awards, and has served as principal or co-investigator in several major clinical trials across various therapeutic areas. In addition, he has served in scientific and medical advisory capacities to such companies as GSK, Medtronic plc and Bayer.

Dr. Semigran earned A.B., A.M. and M.D. degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General.

Mike Acker
Mike Acker
Senior Investigator
Novartis
Mike Acker
Senior Investigator
Novartis

For almost 10 years, Mike has been focused on the discovery and optimization of small molecule therapies to improve patients’ lives. Mike is a Senior Investigator II and currently leads the Oncology Biological Chemistry Group at the Novartis Institutes for BioMedical Research where his team supports early assay development and medicinal chemistry efforts to identify clinical candidate small molecules and elucidate their mechanism of action. The team seeks to bridge the gap between biochemical and cellular assays to gain a better understanding of the complex biology that drives disease. 

Mike is a classically trained enzymologist and biochemist and received his Ph.D. from Johns Hopkins University School of Medicine, working with Dr. Jon R. Lorsch in the field of eukaryotic translation initiation. Prior to joining Novartis, Mike was a Helen Hay Whitney Postdoctoral Fellow with Dr. Christopher T. Walsh at Harvard Medical School where he led the bioengineering of a bacterium for production of new natural product antibiotics to treat MRSA. His team is currently interrogating a number of high-profile cancer targets including signaling kinases, epigenetic enzymes and transcription factors, in search of small molecule modulators with novel mechanisms of action.

Dario Doller
Dario Doller
Director, Medicinal Chemistry
Sunovion Pharmaceuticals
Dario Doller
Director, Medicinal Chemistry
Sunovion Pharmaceuticals

Dario is currently Director, Medicinal Chemistry at Sunovion Pharmaceuticals, where teams discover new treatments for CNS disorders

Since 2006, he has been immersed in drug discovery of allosteric modulators of membrane-bound targets key to brain function (GPCRs, ion channels and transporters)

Dario’s efforts converge at the interface of chemistry and biology. He has contributed to the understanding of allosteric paradoxes like “flat SAR”, binding-function disconnects, and super-physiological function. 

He was the editor of the book Allosterism in Drug Discovery, published by the Royal Society of Chemistry in 2017.

He earned a PhD degree in Organic Chemistry from the University of Buenos Aires, Argentina, in 1989. 

Following postdoctoral work with Sir Derek Barton at Texas A&M University, in 1992, Dario began his industrial research career, at organizations including Schering-Plough Research Institute, 3-Dimensional Pharmaceuticals, Gliatech, Neurogen, Lundbeck, CoNCERT and Sage, as well as his own consulting firm, Alcyoneus ScienceWorks.

Jean-Philippe Rocher
Jean-Philippe Rocher
Head of Discovery - Chemistry
Addex Therapeutics
Jean-Philippe Rocher
Head of Discovery - Chemistry
Addex Therapeutics

Jean-Philippe Rocher is Head of Discovery in Chemistry at Addex. He returned to Addex from Pierre Fabre where he was Director of CNS Programs from March 2014 to May 2018.

Joining Addex at its inception in 2002, Dr. Rocher established the company’s chemistry capabilities and building Addex small molecule allosteric modulator chemistry platform including a library which delivered leads towards > 15 targets.

He has initiated / supervised medicinal chemistry efforts of discovery projects leading to 4 positive phase IIa molecules (mGlu5 NAM: raseglurant and dipraglurant; mGlu2 PAM: ADX71449; sigma2, 5HT2a antagonist: MIN101).

Prior to joining Addex, Dr. Rocher was director of chemistry at Devgen NV (Gent, Belgium), senior research scientist for GlaxoSmithKline KK (Tsukuba, Japan), scientific project leader in CNS at Mitsubishi Tanabe (Yokohama, Japan) and Head of Drug Discovery Unit for Battelle (Geneva, Switzerland). He started his career as a research scientist in the dermatology research centre of Galderma in 1987.

 

2019 Agenda

  • Wednesday, November 20th 2019
Wednesday, November 20th 2019
8.00am
Registration, Breakfast & Networking
9:00am
Chair’s Opening Remarks & Setting the Scene

Adrian Gill, Vice President of Chemistry & CMC, Revolution Medicines

9:10am
Keynote Presentation: Allosteric Modulators - Where We Are and How We Got Here

Bob Copeland, Chief Scientific Officer, Accent Therapeutics

9:35am
Panel Discussion: Building Todays Foundations for Tomorrow's Clinical Trials

Jean-Philippe Rocher, Head of Discovery – Chemistry, Addex Therapeutics

Maria-Jesus Blanco, Senior Director of Medicinal Chemistry, Sage Therapeutics

Mike Acker, Senior Investigator, Novartis

10:15am
Morning Refreshments & Speed Networking

Case Studies

11:00am
Presentation: A Deep-dive into Sage Therapeutics Allosteric Program

Maria-Jesus Blanco, Senior Director of Medicinal Chemistry, Sage Therapeutics

11:25am
Presentation: MyoKardia’s Approach to Treating Heart Conditions with Allostery

Marc Semigran, Senior Vice President of Medical Sciences, MyoKardia

11:50pm
Presentation: EnABLing Discovery of Allosteric Enzyme Modulators: New Mechanisms of Inhibition for BCR-ABL and SHP2

Mike Acker, Senior Investigator, Novartis

12:25pm
Lunch & Networking
1:55pm
Presentation: An In-depth look into Addex Therapeutics Programs

Jean-Philippe Rocher, Head of Discovery – Chemistry, Addex Therapeutics

2:20pm
Presentation: Overcoming Drug-Resistant EGFR Mutants in Non-Small cell Lung Cancer with Mutant-Selective Allosteric Inhibitors

Michael Eck, Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Dana-Farber Cancer Institute

2:45pm
Presentation: Bringing Allostery to the Forefront of Drug Discovery and Development with HotSpot Therapeutics

Geraldine Harriman, Co-Founder & CSO, HotSpot Therapeutics

3:10pm
Afternoon Refreshments & Networking
4:10pm
Presentation: Translating Frontier Cancer Targets Using Multiple Allosteric Approaches

Adrian Gill, Vice President of Chemistry & CMC, Revolution Medicines

4:35pm
Panel Discussion: The In’s and Outs of Identifying Allosteric Sites

Pascal Fortin, Senior Vice President, Relay Therapeutics

Geraldine Harriman, Co-Founder & Chief Scientific Officer, HotSpot Therapeutics

Dario Doller, Director, Medicinal Chemistry, Sunovion Pharmaceuticals

5:15pm
Chair's Closing Remarks

Adrian Gill, Vice President of Chemistry & CMC, Revolution Medicines

5:25pm
End of TAM Summit 2019
Download Agenda

Partnerships

Our attendees tell us that one of the main reasons they attend our summits is to advance partnership discussions and forge new business relationships.  To facilitate this (and help us to fund the event) we have a limited number of partnership opportunities. This means that our partners can be confident they can have the meaningful conversations they seek – and our attendees know that the composition of the audience is just right.

We invite you to get in touch for a no-obligation conversation.  We will share our audience data with you and help you determine whether this summit is the right fit for you.

Contact Us +
Partnerships

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration